Enzymatica AB (publ) (STO:ENZY)

Market Cap	810.74M
Revenue (ttm)	45.58M
Net Income (ttm)	-53.18M
Shares Out	242.74M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	598,651
Average Volume	300,091
Open	3.220
Previous Close	3.280
Day's Range	2.940 - 3.700
52-Week Range	1.340 - 3.960
Beta	0.22
RSI	84.87
Earnings Date	Feb 18, 2025

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2024, Enzymatica AB's revenue was 45.58 million, a decrease of -10.47% compared to the previous year's 50.90 million. Losses were -53.18 million, 6.94% more than in 2023.